medigraphic.com

2011, Number 2

<< Back Next >>

Rev Hematol Mex 2011; 12 (2)

Quality of life in patients with hematological diseases in Northeast Mexico

Jaime-Pérez JC, Sandoval-Villa CC, Marfil-Rivera LJ, Rodríguez-Martínez M, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Gómez-Almaguer D

Language: Spanish
References: 25
Page: 62-67
PDF size: 89.06 Kb.


ABSTRACT

Background: Quality of Life (QoL) is defined as the absence of defect or disease accompanied by a sense of wellbeing. Thus, this concept is a multidimensional structure which involves physical, psychological and social factors of the illness and its treatment.
Objective: We evaluated QoL in hematological patients from northern Mexico being treated at a reference center
Material and methods: A prospective observational study was carried out on patients over 18 years old received a HRQL questionnaire plus the Spanish version of the COOP/WONCA charts. Patients were divided by diagnosis; statistical analysis was performed. Questionnaires with incomplete or duplicated data were excluded.
Results: 500 questionnaires were applied; 360 to the control group, 105 to hematological patients, 35 were excluded. For the malignant group patients with acute lymphoblastic leukemia (ALL) presented alterations in social activity, chronic granulocytic leukemia (CGL) in physical fitness and daily activity, acute myeloid leukemia (AML) in social activity, non Hodgkin lymphoma (NHL) in physical fitness, social and daily activities, and overall health parameters, Hodgkin disease (HD) in overall health, and multiple myeloma (MM) in emotional distress, social and daily activities, overall health and QoL perception. For patients in the benign group those with policythemia vera (PV) reported decreased physical fitness, thrombophilia (TP) emotional distress, idiopathic thrombocytopenic purpura (ITP) greater pain, and autoimmune hemolytic anemia (AIHA) better results than the control group. Patients receiving a hematopoietic transplant (HSCT) had better results in QoL.
Conclusions: Patients with MM refer the worst QoL. For all the diagnosed hematological diseases, patients receiving BMT as therapy showed the better results.


REFERENCES

  1. Paterson C. Seeking the patient’s perspective: a qualitative assessment of EuroQol, COOP-WONCA charts and MYMOP. Qual Life Res 2004;13(5): 871-81.

  2. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989;27(3 Suppl):S217-32.

  3. Monés J. ¿Se puede medir la calidad de vida?¿Cuál es su importancia? Cir Esp 2004;76:71-77.

  4. Smith SK, Zimmerman S, et al. Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer 2009;115(14):3312-3323.

  5. Shanafelt TD, Bowen DA, et al. The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia. Leuk Res 2009;33(2):263-270.

  6. Arden-Close E, Absolom K, et al. Gender differences in selfreported late effects, quality of life and satisfaction with clinic in survivors of lymphoma. Psycho-Oncology 2010; 10.1002/pon.1835.

  7. Efficace F, Kemmler G, et al. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 2008;44(11):1497-1506.

  8. Lizan Tudela L, Reig Ferrer A. Evaluation in the clinic of health-related quality of life: the COOP/WONCA cartoons. Aten Primaria 2002;29(6):378-384.

  9. Guyyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-629.

  10. Alonso J, Prieto L, et al. The Spanish version of the Nottingham Health Profile: a review of adaptation and instrument characteristics. Qual Life Res 1994;3:385-393.

  11. Tchen N, Souberyan P, Eghbali H. Quality of life in patients with aggressive non- Hodking`s Lymphoma. Validadtion of the medical outcomes study shoth form 20 and the Rotterdam symptom check list in older patients. Crit Rev Oncol Hematol 2002;43:219-226.

  12. Hahn EA, Glendenning GA. Quality of life on imatinib. Semin Hematol 2003;40(2 Suppl 2):31-36.

  13. Messerer D, Engel J, et al. Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica 2008;93(6):826-833.

  14. Mols F, Aaronson NK, et al. Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer 2007;109(8):1659-1667.

  15. Arden-Close E, Pacey A, et al. Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique. Leuk Lymphoma 2010;51(4):628-640.

  16. Drigan R, et al. Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia. Med Pediatr Oncol1992; 20(1):13-21.

  17. Cocks K, Cohen D, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007;43(11):1670-1678.

  18. Hartley-Brown MA, Sullivan DM, et al. State-of-the-Art Management of Complications of Myeloma and Its Treatment. Adv Hematol 2010;343-389.

  19. Steensma DP, Heptinstall KV, et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internetbased survey. Leuk Res 2008;32(5):691-698.

  20. Wingard JR, Huang IC, et al. Factors associated with Self-reported Physical and Mental Health after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2010;16:1682-1692.

  21. Mohty M, et al. Long-term physiological side effects after allogeneic bone marrow transplantation. Hematology An Soc Hematol Educ Program 2010;229-236.

  22. Lancet JE, Giralt S. Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant. J Natl Compr Canc Netw 2008;6(10):1017-1025.

  23. Le RQ, Bevans M, et al. Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010;16(8):1162-1170.

  24. Hoffman R. Quality of life issues in patients with essential thrombocythemia and polycythemia vera. Semin Oncol 2002;29(3 Suppl 10):3-9.

  25. von Mackensen S, et al. Development of a disease-specific quality of life questionnaire for children & adolescents with idiopathic thrombocytopenic purpura (ITP-QoL). Pediatr Blood Cancer 2006;47(5 Suppl):688-691.




2020     |     www.medigraphic.com